Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 7687098, 8 pages
https://doi.org/10.1155/2017/7687098
Review Article

Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

1Preventive Medicine Department, Grade 2014, School of Public Health, Qingdao University, Shandong, China
2Clinical Medicine Department, Grade 2014, Medical College, Qingdao University, Shandong, China
3School of Public Health, Qingdao University, Qingdao, China
4Physiology Department, Medical College, Qingdao University, Shandong, China
5Special Medicine Department, Medical College, Qingdao University, Shandong, China

Correspondence should be addressed to Jing Dong; moc.liamtoh@6gnijgnod

Received 17 May 2017; Revised 24 July 2017; Accepted 3 December 2017; Published 28 December 2017

Academic Editor: Daniela Foti

Copyright © 2017 Ting Zhai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The role of nesfatin-1 in glucose homeostasis has been investigated previously. However, although numerous studies have examined the relationships between circulating nesfatin-1 levels and type 2 diabetes, the conclusions are contradictory. We aimed to probe the relationship between circulating nesfatin-1 levels and type 2 diabetes by meta-analysis. Seven studies including 328 type 2 diabetes patients and 294 control subjects were included. Although there was no obvious difference in circulating nesfatin-1 levels between patients with type 2 diabetes and the control group (MD = −0.04; 95% CI = −0.32 to −0.23), subgroup analysis showed higher nesfatin-1 levels in newly diagnosed type 2 diabetes patients (MD = 0.59; 95% CI = 0.45 to 0.74) and significantly lower nesfatin-1 levels in type 2 diabetes patients receiving antidiabetic treatment (MD = −0.26; 95% CI = −0.33 to −0.20). In conclusion, the analysis supports a relationship between circulating nesfatin-1 levels and type 2 diabetes, where newly diagnosed type 2 diabetes was associated with an elevated Nesfatin-1 level, and type 2 diabetes patients receiving antidiabetic treatment showed lower circulating nesfatin-1 levels.